Economic burden of cardiovascular diseases in the enlarged European Union

Leal, José; Luengo-Fernández, Ramón; Gray, Alastair; Petersen, Sophie; Rayner, Mike

doi:10.1093/eurheartj/ehi733

Cited by 603 publications

(453 citation statements)

References 7 publications

Supporting

Mentioning

403

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, cost-effective scenarios were found for treatments other than alendronate, providing credible alternative options for patients unable to take alendronate. Similar conclusions have also been reached in separate studies for most second line treatments [106,[109][110][111][112][113][114]. There are differences, however, in the spectrum of efficacy of these alternatives across different fracture sites that will determine their suitability in the clinical management of individuals.…”

Section: Cost-effectiveness Of Pharmaceutical Interventionssupporting

confidence: 67%

“…This has been explored for the use of alendronate [107,116] risedronate [114], denosumab [113], raloxifene [117] and strontium ranelate [111]. In the case of generic alendronate treatment compared to no treatment was found to be costeffective at a 10-year probability of a major fracture of 7.5 % in a UK setting (Fig.…”

Section: Cost-effectiveness Of Pharmaceutical Interventionsmentioning

confidence: 99%

“…The cost of coronary heart disease and cerebrovascular disease in the European Union (25 countries) has been estimated at approximately €45 billion and €34 billion, respectively, at 2003 prices [114]. For coronary heart disease, healthcare costs, productivity losses, and informal care comprised 51 %, 34 % and 15 %, respectively.…”

Section: Cost Of Osteoporosis Compared To Other Diseasesmentioning

confidence: 99%

“…For cerebrovascular disease, healthcare costs, productivity losses, and informal care comprised 61 %, 18 % and 21 % respectively. Costs for pharmacological treatment accounted for 3 % of the total costs for cerebrovascular disease [114], somewhat lower than for osteoporosis.…”

Section: Cost Of Osteoporosis Compared To Other Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Osteoporosis in the European Union: medical management, epidemiology and economic burden

Hernlund¹,

Svedbom²,

Ivergård³

et al. 2013

Arch Osteoporos

2,133

1,048

View full text Add to dashboard Cite

Summary This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27). Introduction Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond. Methods The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010.Results Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at € 37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining.

show abstract

Section: Cost-effectiveness Of Pharmaceutical Interventionssupporting

confidence: 67%

Section: Cost-effectiveness Of Pharmaceutical Interventionsmentioning

confidence: 99%

Section: Cost Of Osteoporosis Compared To Other Diseasesmentioning

confidence: 99%

Section: Cost Of Osteoporosis Compared To Other Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Osteoporosis in the European Union: medical management, epidemiology and economic burden

Hernlund¹,

Svedbom²,

Ivergård³

et al. 2013

Arch Osteoporos

2,133

1,048

View full text Add to dashboard Cite

show abstract

“…1 The financial burden is equally immense; the annual cost to the European Union is estimated at h169 billion, 62% of which is directly spent on healthcare provision. 2 Given this significant health-care burden, there exists an enormous potential for risk factor modification and preventative medicine. Ten years ago, the EUROASPIRE I (European Action on Secondary Prevention by Intervention to Reduce Events) survey of patients with established coronary heart disease (CHD) in nine European countries confirmed the substantial potential for cardiac risk factor modification.…”

mentioning

confidence: 99%

Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines

et al. 2006

View full text Add to dashboard Cite

Economic Cost of Visual Impairment in Japan

Roberts¹

2010

Arch Ophthalmol

View full text Add to dashboard Cite

Objective: To quantify the total economic cost of visual impairment in Japan. Methods: A prevalence-based approach was adopted using data on visual impairment, the national health system, and indirect costs to capture the economic impact of visual impairment in 2007. Results: In 2007, visual impairment affected more than 1.64 million people in Japan and cost around ¥8785.4 billion (US $72.8 billion) across the economy, equivalent to 1.7% of Japan's gross domestic product. The loss of well-being (years of life lost from disability and premature mortality) cost ¥5863.6 billion (US $48.6 billion). Direct health system costs were ¥1338.2 billion (US $11.1 billion). Other financial costs were ¥1583.5 billion (US $13.1 billion), including productivity losses, care takers' costs, and efficiency losses from welfare payments and taxes. Community care was the largest component of other financial costs and was composed of paid and unpaid services that provide home and personal care to people with visual impairment. The findings of this study are in line with those of similar studies in Australia and the United States. Conclusions: Visual impairment imposes substantial costs on society, particularly to individuals with visual impairment and their families. Eliminating or reducing disabilities from visual impairment through public awareness of preventive care, early diagnosis, more intensive disease treatment, and new medical technologies could significantly improve the quality of life for people with visual impairment and their families, while also potentially reducing national health care expenditure and increasing productivity in Japan. The results of this study should provide a first step in helping policymakers evaluate policy effects and to prioritize research expenditures.

show abstract

Economic burden of cardiovascular diseases in the enlarged European Union

Cited by 603 publications

References 7 publications

Osteoporosis in the European Union: medical management, epidemiology and economic burden

Osteoporosis in the European Union: medical management, epidemiology and economic burden

Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines

Economic Cost of Visual Impairment in Japan

Contact Info

Product

Resources

About